LNP mediated CRISPR/Cas9 Gene Editing Platform

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite its transformative potential, the widespread application of CRISPR/Cas9 gene editing remains constrained by inefficient in vivo delivery, off-target effects, and immunogenicity concerns associated with viral vectors. Our LNP-Mediated CRISPR/Cas9 Gene Editing Platform addresses these barriers by harnessing proprietary lipid nanoparticle formulations for safe, targeted, and non-viral delivery of ribonucleoprotein complexes or nucleic acid cargo. We offer end-to-end custom services, from guide RNA design and LNP formulation to in vitro and in vivo functional validation, tailored to your specific cell type and disease model. With high editing efficiency, low cytotoxicity, and scalable manufacturing, our platform empowers you to accelerate therapeutic discovery and achieve precise genomic modifications with confidence and reproducibility.

Introduction

LNP-mediated CRISPR/Cas9 delivery employs biocompatible nanocarriers to encapsulate and transport Cas9 mRNA or ribonucleoprotein complexes, along with synthetic guide RNAs, into target cells via endocytic pathways, enabling transient and non-viral genome engineering. This approach achieves highly efficient, site-specific DNA cleavage and repair, while minimizing off-target mutations and innate immune activation compared to viral systems. In CAR therapy, this platform enables precise knock-in of chimeric antigen receptor constructs at safe-harbor loci or targeted disruption of inhibitory checkpoints in autologous or allogeneic T cells, thereby enhancing antitumor potency, persistence, and manufacturing scalability for next-generation cell-based immunotherapies.

Fig.1 CRISPR therapies delivered via lipid nanoparticles. (OA Literature) Fig.1 CRISPR-based lipid nanoparticle therapeutics.¹

Our Service

By encapsulating advanced CRISPR machinery within optimized lipid nanoparticles, we ensure high transfection efficiency, minimal immunogenicity, and robust target gene disruption. We offer tailored, scalable solutions to accelerate your workflows from target validation to clinical translation.

What We Can Offer

Our platform offers a versatile LNP-based delivery suite tailored to your gene editing needs, enabling co-delivery of mRNA and sgRNA for transient expression, direct RNP-mediated hit-and-run editing, and large-cargo multiplex engineering, all with high efficiency and minimal off-target activity.

Featured services of LNP-mediated CRISPR/Cas9 gene editing platform at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Immune cells: Peripheral blood mononuclear cells (PBMCs) or purified T cells / NK cells.
Cas9 mRNA.
CAR mRNA.

Key Steps:

Workflow of LNP-mediated CRISPR/Cas9 gene editing platform at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Verified Cell product.
Functional validation data.

Key Advantages

High Safety Profile with Zero Integration Risk: By delivering transient mRNA rather than viral DNA, the platform eliminates the risk of insertional mutagenesis while minimizing immunogenicity to allow for flexible multi-dosing.
Reduced Off-Target Effects via Transient Expression: The rapid degradation of LNP-delivered mRNA ensures short-lived Cas9 expression, significantly restricting duration of cleavage activity and enhancing overall editing precision.
Superior Cargo Capacity for Complex Editing: Unbound by the strict packaging limitations of traditional viral vectors, the platform easily encapsulates large genetic payloads, including Cas9 mRNA, sgRNAs, and donor templates, for multiplex editing.

FAQ

Q1: What forms of CRISPR/Cas9 components are encapsulated in your LNPs?

A1: We primarily encapsulate Cas9 mRNA and sgRNA to ensure transient expression and maximum safety. For specific knock-in projects, we can also co-encapsulate or co-deliver donor DNA templates.

Q2: How does your platform minimize off-target effects compared to viral vectors?

A2: Unlike viral vectors that cause prolonged Cas9 expression, our LNP platform delivers mRNA that undergoes rapid intracellular degradation. This transient expression restricts the window of Cas9 activity, significantly reducing off-target cleavage while maintaining high on-target editing efficiency.

Q3: What is the maximum cargo capacity of your LNP platform?

A3: One of the greatest advantages of our non-viral LNP platform is that it is not restricted by the strict size limitations of viral vectors. It easily accommodates large Cas9 mRNA, multiple sgRNAs for multiplex editing, and donor templates simultaneously.

Why Choose Us?

Choose our platform for unparalleled precision and safety in therapeutic gene editing. By integrating high-capacity, non-integrating lipid nanoparticles with transient CRISPR expression, we eliminate viral insertion risks and minimize off-target effects. Benefit from our robust, scalable manufacturing and tunable tissue targeting to accelerate your next-generation cell and gene therapies.

Customer Reviews

"We utilized this LNP-CRISPR/Cas9 platform for our liver-targeted gene silencing program. The LNP formulation demonstrated exceptional in vivo delivery efficiency with over 90% knockout success in target tissues, significantly accelerating our preclinical proof-of-concept timeline." Dr. Aris Thorne.

"Scaling up non-viral gene editing for primary human T-cells has always been a bottleneck for our lab. This platform’s highly consistent LNP screening and strict quality control ensured robust, reproducible multiplex gene editing across multiple patient donors." Prof. F* G*.

How to contact us?

Partner with us to accelerate your therapeutic breakthroughs. Whether you require standard hepatic targeting or custom extrahepatic formulations, our experts are ready to optimize your project. Contact us today to request a comprehensive quote and discover how our scalable, high-precision platform can transform your cellular immunotherapies.

Reference

Wang, Shuting et al. "Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment." Cells vol. 13,7 568. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cells13070568.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.